References

Desmoplastic small round cell tumor 20 years after its discovery

10.2217/fon.15.32 · 2015 · External reference

A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor

10.1097/00000478-199204000-00010 · 1992 · External reference

Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor

1994 · External reference

Results of multimodal treatment for desmoplastic small round cell tumors

10.1016/j.jpedsurg.2004.09.046 · 2005 · External reference

Clinical perspective on desmoplastic small round-cell tumor

10.1159/000081323 · 2004 · External reference

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients

10.1016/j.suronc.2019.04.002 · 2019 · External reference

Desmoplastic small round cell tumor: a nationwide study of a rare sarcoma

10.1002/jso.25071 · 2018 · External reference

EWSR1 fusions: Ewing sarcoma and beyond

10.1002/cncy.22239 · 2020 · External reference

Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets

10.1146/annurev-pathol-011110-130237 · 2012 · External reference

The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour

10.1038/ng1197-309 · 1997 · External reference

Genomic and proteomic alterations in desmoplastic small round blue-cell tumors

10.1200/po.17.00170 · 2018 · External reference

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

10.1242/dmm.047621 · 2022 · External reference

HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor

10.1158/1078-0432.ccr-24-1835 · 2024 · External reference

High expression level of ERBB2 and efficacy of trastuzumab deruxtecan in desmoplastic small round cell tumour: a monocentric case series report

10.1016/j.esmoop.2025.104133 · 2025 · External reference

Near complete response with trastuzumab deruxtecan in a teenager with relapsing metastatic desmoplastic small round cell tumor

10.1002/pbc.32009 · 2025 · External reference

Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer

10.1056/nejmoa2203690 · 2022 · External reference

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer

10.1056/nejmoa2407086 · 2024 · External reference

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

10.1038/s41591-023-02478-2 · 2023 · External reference

Antitumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression

10.1158/1535-7163.mct-25-0437 · 2026 · External reference

Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo

10.1007/s00432-020-03211-z · 2020 · External reference

A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers

10.1038/s41416-021-01476-w · 2021 · External reference

SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma

10.1158/1078-0432.ccr-14-2112 · 2015 · External reference

Replication stress is an actionable genetic vulnerability in desmoplastic small round cell tumors

10.1158/0008-5472.can-23-3603 · 2025 · External reference

ACR-368, a CHK1/2 kinase inhibitor, in patients with relapsed or refractory desmoplastic small round cell tumor: phase I/II trial results

10.1200/oa-24-00095 · 2025 · External reference

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy

10.1007/s00280-006-0280-z · 2007 · External reference

Desmoplastic small round cell tumors and the role of androgen receptors

10.1007/s11864-025-01334-4 · 2025 · External reference

The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

10.1038/s41467-022-30710-z · 2022 · External reference

Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics

10.3389/fcell.2024.1442488 · 2024 · External reference

Implementing a comprehensive translational oncology platform: from molecular testing to actionability

10.1186/s12967-018-1733-y · 2018 · External reference

Near-optimal probabilistic RNA-seq quantification

10.1038/nbt.3519 · 2016 · External reference

A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations

10.1158/1078-0432.ccr-17-3509 · 2018 · External reference

TCPA: a resource for cancer functional proteomics data

10.1038/nmeth.2650 · 2013 · External reference

A pan-cancer proteomic perspective on The Cancer Genome Atlas

10.1038/ncomms4887 · 2014 · External reference

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

10.1038/ng.3593 · 2016 · External reference

ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information

10.1093/bioinformatics/btw216 · 2016 · External reference

Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samples

10.1093/narcan/zcaf025 · 2025 · External reference

Molecular signatures of BRCAness analysis identifies PARP inhibitor niraparib as a novel targeted therapeutic strategy for soft tissue sarcomas

10.7150/thno.45763 · 2020 · External reference

SCANPY: large-scale single-cell gene expression data analysis

10.1186/s13059-017-1382-0 · 2018 · External reference

Deep generative modeling for single-cell transcriptomics

10.1038/s41592-018-0229-2 · 2018 · External reference

decoupleR: ensemble of computational methods to infer biological activities from omics data

10.1093/bioadv/vbac016 · 2022 · External reference

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

10.1073/pnas.0506580102 · 2005 · External reference

The reactome pathway knowledgebase 2024

10.1093/nar/gkad1025 · 2024 · External reference

A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility

10.1097/pai.0b013e31802ced25 · 2007 · External reference

Multi-site desmoplastic small round cell tumors are genetically related and immune-cold

10.1038/s41698-022-00257-9 · 2022 · External reference

The regulation role of interferon regulatory factor-1 gene and clinical relevance

10.1016/j.humimm.2014.09.015 · 2014 · External reference

T cell exclusion, immune privilege, and the tumor microenvironment

10.1126/science.aaa6204 · 2015 · External reference

CIA: unveiling cellular identities with cluster-independent annotation in single-cell RNA sequencing data for comprehensive cell type characterization and exploration

10.1186/s12859-025-06320-z · 2025 · External reference

Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs

10.1016/j.xcrm.2024.101582 · 2024 · External reference

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer

10.1038/modpathol.2009.37 · 2009 · External reference

Unresolved reference

External reference

Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, is effective in pediatric malignancies: a report by the pediatric preclinical testing consortium

10.1158/1535-7163.mct-21-0758 · 2022 · External reference

Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children’s Oncology Group

10.1200/jco.2011.37.4546 · 2012 · External reference

Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer

10.1016/j.ejca.2018.08.001 · 2018 · External reference

Androgen receptor activity in T cells limits checkpoint blockade efficacy

10.1038/s41586-022-04522-6 · 2022 · External reference

Elevated tumor-associated androgen receptor activity correlates with poor immune infiltration and immunotherapy response across cancer types

10.1158/2767-9764.crc-25-0409 · 2026 · External reference

gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair

10.1016/j.molcel.2005.10.003 · 2005 · External reference

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

10.1073/pnas.1205943109 · 2012 · External reference

SLFN11 blocks stressed replication forks independently of ATR

10.1016/j.molcel.2018.01.012 · 2018 · External reference

SLFN11 inhibits checkpoint maintenance and homologous recombination repair

10.15252/embr.201540964 · 2016 · External reference

Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

10.1158/1078-0432.ccr-18-2728 · 2019 · External reference

Conventional DNA-damaging cancer therapies and emerging cGAS-STING activation: a review and perspectives regarding immunotherapeutic potential

10.3390/cancers15164127 · 2023 · External reference